Nouveau Life Pharmaceuticals Inc. (Pink Sheets: NOUV), a provider of quality all-natural dietary supplements, announced today that the Company is in talks with international mass distribution firms.
Nouveau Life is in talks with mass distributors in Canada and the UK to sell the Nouveau Life's products in those markets.
"The distribution firms with which we are speaking are well-regarded in their respective countries," stated Nouveau Life CEO Melissa Walker. "These distributors have extensive knowledge of the regulatory requirements in each country. They know how to navigate their governments' oversight systems and will help Nouveau Life in the licensing processes. They also have well-established sales networks in place. These are growing markets. We see great potential for Nouveau Life to penetrate these markets."
Seventy-one percent of Canadian adults report using a natural health product, with 38 percent reporting they use at least one daily. Canada requires that dietary supplements be licensed prior to market entry. The Natural Health Products Directorate (NHPD), a branch of Health Canada, is responsible for granting licenses for dietary supplements.
In the UK, the dietary supplement and vitamins market is valued at over $1.1 billion (U.S.). The government agency National Health Services (NHS) is responsible for regulating and licensing dietary supplements in the UK.
Nouveau Life currently sells four specialty supplements: Azul Instant™, Azul: Male Enhancer™, New Life Naturals: For Her Senses™, and New Life Naturals: For Your Weight Loss. The Company has plans to release another four products to the public in the coming weeks. All of Nouveau Life's supplements can be purchased by visiting www.nlpnaturals.com.
About Nouveau Life Pharmaceuticals
The Company, formerly known as Hybrid Fuels, Inc., was incorporated in the state of Nevada in 1998 as Polo Equities. It has primarily been a development stage company with management focused on developing innovative business opportunities and further advancing technologies.
Forward-Looking Statements - This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause future results to differ materially from the forward-looking statements. You should consider these factors in evaluating the statements herein, and not rely on such statements. The forward-looking statements in this release are made as of the date hereof and Nouveau Life Pharmaceuticals, Inc. undertakes no obligation to update such statements.
NOUVEAU LIFE PHARMACEUTICALS, INC.
SOURCE Nouveau Life Pharmaceuticals, Inc.